Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency

Subcutaneous IgG treatment for primary immunodeficiencies (PI) is particularly well suited for children because it does not require venous access and is mostly free of systemic adverse events (AEs). In a prospective, open-label, multicenter, single-arm, Phase III study, 18 children and five adolesce...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Borte, Michael, Pac, Malgorzata, Serban, Margit, Gonzalez-Quevedo, Teresa, Grimbacher, Bodo, Jolles, Stephen, Zenker, Othmar, Neufang-Hueber, Jutta, Belohradsky, Bernd
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2011
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3221851/
https://ncbi.nlm.nih.gov/pubmed/21674136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-011-9557-z
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items